- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT07540871
Thermoses as a Way to Provide Human Milk to Toddlers in Daycare
May 5, 2026 updated by: University of Florida
Parents and daycare providers for children between the ages of 1 and 3 years old at participating daycares will be asked to join this study.
Parents will be provided with three thermoses designed to keep breastmilk at a safe temperature for 15+ hours, and asked to use each thermos for four weeks.
Parents and daycare providers will be asked to complete weekly questionnaires about any problems they experience with a thermos.
Study staff will check the temperature of the milk each day before lunch and afternoon snack to ensure the milk is at a safe temperature for consumption.
Study Overview
Status
Not yet recruiting
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Estimated)
15
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Diana H Taft, PhD
- Phone Number: 352-294-3755
- Email: dianataft@ufl.edu
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Yes
Description
Inclusion Criteria:
- Must work at a participating daycare OR send a child to a participating daycare
- Must work with children between the ages of 1 and 3 years at least 3 days a week, with at least 1 participating child in the classroom (daycare providers)
- Must intend to provide breastmilk to a child ages 1 to 3 years for lunch and/or afternoon snack (parent)
Exclusion Criteria:
-
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Other: Thermos 1
First of three study thermoses
|
Parents will be provided with 3 different thermoses, all marketed as capable of keeping breastmilk at a safe temperature for 15 or more hours.
The interventions are numbered to match study assigned thermos number.
|
|
Other: Thermos #2
Second of three study thermoses
|
This is the second of the three thermoses used in the study
|
|
Other: Thermos #3
Third of three study thermoses
|
This is the third of the three different thermoses
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Breastmilk temperature at lunch
Time Frame: Measured daily for 4 weeks
|
Measured daily for 4 weeks
|
|
Breastmilk temperature at afternoon snack
Time Frame: Measured daily for 4 weeks
|
Measured daily for 4 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Daycare provider report of thermos problems
Time Frame: Weekly questionnaires for 12 weeks
|
Daycare providers will be asked to report using a scale listed as no issues, minor issues, moderate issues, and severe issues
|
Weekly questionnaires for 12 weeks
|
|
Parent report of thermos problems
Time Frame: Measured weekly for 12 weeks
|
Parents will be asked to report using a scale listed as no issues, minor issues, moderate issues, and severe issues
|
Measured weekly for 12 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Estimated)
June 1, 2026
Primary Completion (Estimated)
November 1, 2026
Study Completion (Estimated)
December 1, 2027
Study Registration Dates
First Submitted
April 14, 2026
First Submitted That Met QC Criteria
April 14, 2026
First Posted (Actual)
April 20, 2026
Study Record Updates
Last Update Posted (Actual)
May 8, 2026
Last Update Submitted That Met QC Criteria
May 5, 2026
Last Verified
April 1, 2026
More Information
Terms related to this study
Other Study ID Numbers
- IRB202600459
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
YES
IPD Plan Description
We will share deidentified responses to weekly questionnaires when results are published
IPD Sharing Time Frame
We will make IPD available on publication by sharing de-identified results as supplemental information to publications.
A blank consent will be available to the journal on request, for as long as the PI is required to maintain such records.
Analytical code will be made available upon publication
IPD Sharing Access Criteria
IPD will be to those who can access the de-identified data as part of the publication
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- ICF
- ANALYTIC_CODE
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Thermos 1
-
Orasis Pharmaceuticals Ltd.Completed
-
University of ThessalyCompleted
-
University of Sao Paulo General HospitalCompletedOveractive Bladder SyndromeBrazil
-
University of Sao Paulo General HospitalCompleted
-
Chulalongkorn UniversityCompletedAllergic RhinitisThailand
-
Montreal Heart InstituteInstitut de Recherches Cliniques de Montreal; Royal Victoria Hospital, Canada; Queen Elizabeth II Health Sciences Centre and other collaboratorsCompletedHypertriglyceridemiaCanada
-
The University of Texas Health Science Center,...National Heart, Lung, and Blood Institute (NHLBI); United States Department... and other collaboratorsCompleted
-
Yonsei UniversityCompletedObese Patients, One Lung VentilationKorea, Republic of
-
Janssen Research & Development, LLCCompletedRelapsed or Refractory Hodgkin LymphomaFrance, Germany
-
Queen Margaret UniversityNHS LothianTerminated